P.3.c.056 Efficacy of ziprasidone in the treatment of schizoaffective disorder:an analysis of 2 fixed-dose, placebo-controlled trials

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies

“…As previous work has shown, although response can occur as early as the first 24 hours (Agid et al, 2006), we find that the PP of early time points appears to increase from week 1 to 2 and onward. Previous studies have shown reasonable predictive validity of early improvement for a 46% PANSS total score improvement at week 2 and a 50% improvement for remission (AUC: response 0.707, remission 0.692) (Schennach-Wolff et al, 2010). Although we made no distinction between first and multiple-episode subjects in our analyses, a higher threshold in the PANSS score within 2 weeks of treatment may well have been more discriminating.…”

“…We pooled data from two similarly designed 6‐week, fixed‐dose, randomized, placebo‐controlled trials (studies 114 and 115) of ziprasidone in hospitalized patients with schizophrenic illness (Daniel et al , ; Rappard et al , ). Following a 3‐day to 7‐day washout period, subjects were randomized to fixed‐dose treatment with ziprasidone (40−160 mg) or placebo.…”

“…Here, we present analyses of placebo‐controlled and comparator studies of ziprasidone in the treatment of schizophrenia. Using retrospective data from the placebo‐controlled trials, we looked at this phenomenon specific to ziprasidone (Daniel et al , ; Rappard et al , ). Additionally, using data from the comparator studies (involving olanzapine and risperidone), we looked at this question generally without regard to which antipsychotic was used (Addington et al , ; Simpson et al , ).…”